Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 129


Estimating the Compressibility of Osmium from Recent Measurements of Ir-Os Alloys under High Pressure.

Sarlis NV, Skordas ES.

J Phys Chem A. 2016 Mar 10;120(9):1601-4. doi: 10.1021/acs.jpca.6b00846. Epub 2016 Feb 25.


Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review.

Parasuraman S, DiBonaventura M, Reith K, Naim A, Concialdi K, Sarlis NJ.

Exp Hematol Oncol. 2016 Feb 1;5:3. doi: 10.1186/s40164-016-0031-8. eCollection 2015.


Minima of the fluctuations of the order parameter of global seismicity.

Sarlis NV, Christopoulos SR, Skordas ES.

Chaos. 2015 Jun;25(6):063110. doi: 10.1063/1.4922300.


A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators.

Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11.


Endothelial growth factor receptor inhibitors in recurrent metastatic cancer of the head and neck.

Misiukiewicz K, Dang RP, Parides M, Camille N, Uczkowski H, Sarlis NJ, Posner M.

Head Neck. 2016 Apr;38 Suppl 1:E2221-8. doi: 10.1002/hed.24083. Epub 2015 Nov 5. Review.


Spatiotemporal variations of seismicity before major earthquakes in the Japanese area and their relation with the epicentral locations.

Sarlis NV, Skordas ES, Varotsos PA, Nagao T, Kamogawa M, Uyeda S.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):986-9. doi: 10.1073/pnas.1422893112. Epub 2014 Dec 29.


Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S.

Int J Gen Med. 2014 Jan 29;7:89-101. doi: 10.2147/IJGM.S51800. eCollection 2014.


Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.

Mitra D, Kaye JA, Piecoro LT, Brown J, Reith K, Mughal TI, Sarlis NJ.

Cancer Med. 2013 Dec;2(6):889-98. doi: 10.1002/cam4.136. Epub 2013 Oct 5.


Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Onco Targets Ther. 2013 Dec 17;7:13-21. doi: 10.2147/OTT.S53348. eCollection 2013.


Minimum of the order parameter fluctuations of seismicity before major earthquakes in Japan.

Sarlis NV, Skordas ES, Varotsos PA, Nagao T, Kamogawa M, Tanaka H, Uyeda S.

Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13734-8. doi: 10.1073/pnas.1312740110. Epub 2013 Aug 5.


Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.

Saba NF, Magliocca KR, Kim S, Muller S, Chen Z, Owonikoko TK, Sarlis NJ, Eggers C, Phelan V, Grist WJ, Chen AY, Ramalingam SS, Chen ZG, Beitler JJ, Shin DM, Khuri FR, Marcus AI.

Head Neck Pathol. 2014 Mar;8(1):66-72. doi: 10.1007/s12105-013-0476-6. Epub 2013 Jul 24.


Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.

Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S.

Leuk Res. 2013 Aug;37(8):911-6. doi: 10.1016/j.leukres.2013.04.017. Epub 2013 May 17.


Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Haddad R, O'Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, Clark J, Sarlis N, Lorch J, Beitler JJ, Limaye S, Riley S, Posner M.

Lancet Oncol. 2013 Mar;14(3):257-64. doi: 10.1016/S1470-2045(13)70011-1. Epub 2013 Feb 13.


Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.

Vaddi K, Sarlis NJ, Gupta V.

Expert Opin Pharmacother. 2012 Nov;13(16):2397-407. doi: 10.1517/14656566.2012.732998. Epub 2012 Oct 10. Review.


Predictability of the coherent-noise model and its applications.

Sarlis NV, Christopoulos SR.

Phys Rev E Stat Nonlin Soft Matter Phys. 2012 May;85(5 Pt 1):051136. Epub 2012 May 25.


Natural time analysis of the Centennial Earthquake Catalog.

Sarlis NV, Christopoulos SR.

Chaos. 2012 Jun;22(2):023123. doi: 10.1063/1.4711374.


The interplay between inhibition of JAK2 and HSP90.

Fridman JS, Sarlis NJ.

JAKSTAT. 2012 Apr 1;1(2):77-9. doi: 10.4161/jkst.20293.


Functional polymorphisms in the insulin-like binding protein-3 gene may modulate susceptibility to differentiated thyroid carcinoma in Caucasian Americans.

Xu L, Mugartegui L, Li G, Sarlis NJ, Wei Q, Zafereo ME, Sturgis EM.

Mol Carcinog. 2012 Oct;51 Suppl 1:E158-67. doi: 10.1002/mc.21900. Epub 2012 Mar 13.


A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE.

Ann Oncol. 2012 Jun;23(6):1640-5. doi: 10.1093/annonc/mdr490. Epub 2011 Oct 19.

Supplemental Content

Loading ...
Support Center